Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Matthew Yurgelun on Pathogenic Mutations in CRC

September 22nd 2016

Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.

Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

September 21st 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Dr. Bekaii-Saab on Differences Between Regorafenib and TAS-102 in CRC

September 20th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses regorafenib and TAS-102. In colorectal cancer.

Dr. Finn on Recent Advances in the Treatment of Liver Cancer

September 20th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses both recent advances in the treatment of patients with liver cancer, as well as the future role that immunotherapy stands to have in this field.

Dr. Bekaii-Saab on Microsatellite Instability in Colorectal Cancer

September 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses microsatellite instability in colorectal cancer.

Dr. El-Khoueiry on the Rationale for Evaluating Nivolumab in Advanced HCC

September 14th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).

Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver Cancer

September 14th 2016

Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

Conflicting Evidence Surfaces on Anti-HCV Drugs for Liver Cancer

September 12th 2016

A new generation of drugs has proved highly effective against the hepatitis C virus but there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma who already have responded to curative treatment.

Expert Describes Potential Therapeutic Vaccine for Advanced HCC

September 12th 2016

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

New Roles May Evolve for Competing Embolization Techniques in HCC

September 12th 2016

Two competing methods of delivering locoregional therapy to patients with hepatocellular carcinoma both have advantages and may be most successful in subgroups of individuals with intermediate-stage disease.

Dr. Do on the Assessment of Tumor Response in Liver Cancer

September 11th 2016

Richard Kinh Gian Do, MD, PhD, radiologist, Memorial Sloan Kettering Cancer Center, discusses the assessment of tumor response in liver cancer.

Dr. Yao on the Milan Criteria in Liver Cancer

September 11th 2016

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC

September 11th 2016

About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.

Nivolumab Maintains Positive Results in Latest HCC Findings

September 11th 2016

Nivolumab continues to post durable responses in patients with advanced hepatocellular carcinoma regardless of whether they had hepatitis B or C or whether they had received prior treatment with sorafenib.

Regorafenib Moves Ahead of Field With Success in Advanced HCC

September 11th 2016

After 9 years of failed trials for once-promising drugs, regorafenib (Stivarga) has emerged as the clear choice for second-line therapy in advanced hepatocellular carcinoma after demonstrating survival improvements for patients whose disease has progressed after systemic treatment.

Dr. Finn on Finding a Biomarker for Patients With HCC

September 10th 2016

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the challenges with determing a biomarker for patients with hepatocellular carcinoma (HCC) in an interview during the 10th Annual Conference of the International Liver Cancer Association (ILCA) in Vancouver, Canada. Finn is the current ILCA president.

Dr. Sherman on Screening Obstacles in Liver Cancer

September 10th 2016

Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the issues oncologists face with screening patients for hepatocellular carcinoma (HCC) in an interview during the 10th International Liver Cancer Association (ILCA) Annual Conference.

Regorafenib Poised as Second-Line Standard of Care in HCC

September 10th 2016

Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.

Early Signals Positive for Immunotherapy Plus Standard Therapy in HCC

September 10th 2016

Early evidence suggests that the combination of locoregional therapy with an immune checkpoint inhibitor is a safe and effective strategy to pursue for patients with advanced hepatocellular carcinoma.

Dr. Zhu on Optimal Second-Line Treatment for Patients With HCC

September 10th 2016

Andrew X. Zhu, MD, PhD, professor of Medicine, Harvard Medical School, director of Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the possibility of an optimal second-line treatment for all patients with hepatocellular carcinoma (HCC).